4 Questions About Johnson & Johnson's Vaccine Answered

By: Maureen Ferran  | 

Johnson & Johnson vaccine
A health care worker holds a dose of the Johnson & Johnson COVID-19 vaccine before administering it at the Klerksdorp Hospital in Klerksdorp, South Africa. PHILL MAGAKOE/AFP via Getty Images

On Friday, Feb. 24, the U.S. Food and Drug Administration (FDA) released the results of its trial of the Johnson & Johnson coronavirus vaccine. The FDA found the vaccine to be safe and effective, and granted the one-dose COVID-19 vaccine emergency use authorization at its advisory panel meeting Saturday, Feb. 27. The company began shipping 3.9 million doses of the vaccine across the United States on Monday, March 1.

Maureen Ferran, a virologist at the Rochester Institute of Technology, explains how this new vaccine works and explores the differences between it and the already approved Moderna and Pfizer-BioNTech vaccines.

Advertisement

1. How Does the Johnson & Johnson Vaccine Work?

The Johnson & Johnson vaccine is what's called a viral vector vaccine. To create this vaccine, the Johnson & Johnson team took a harmless adenovirus — the viral vector — and replaced a small piece of its genetic instructions with coronavirus genes for the  SARS-CoV-2 spike protein.

After this modified adenovirus is injected into someone's arm, it enters the person's cells. The cells then read the genetic instructions needed to make the spike protein and the vaccinated cells make and present the spike protein on their own surface. The person's immune system then notices these foreign proteins and makes antibodies against them that will protect the person if they are ever exposed to SARS-CoV-2 in the future.

The adenovirus vector vaccine is safe because the adenovirus can't replicate in human cells or cause disease, and the SARS-CoV-2 spike protein can't cause COVID-19 without the rest of the coronavirus.

This approach is not new. Johnson & Johnson used a similar method to make its Ebola vaccine, and the AstraZeneca-Oxford COVID-19 vaccine is also an adenovirus viral vector vaccine.

Johnson & Johnson vaccine
The Johnson & Johnson COVID-19 vaccine was 72 percent effective at preventing all COVID-19 and 86 percent effective at preventing severe cases of the disease.
PHILL MAGAKOE/AFP via Getty Images

Advertisement

2. How Effective Is It?

The FDA's analysis found that, in the U.S., the Johnson & Johnson COVID-19 vaccine was 72 percent effective at preventing all COVID-19 and 86 percent effective at preventing severe cases of the disease. While there is still a chance a vaccinated person could get sick, this suggests they would be much less likely to need hospitalization or to die from COVID-19.

A similar trial in South Africa, where a new, more contagious variant is dominant, produced similar results. Researchers found the Johnson & Johnson vaccine to be slightly less effective at preventing all illness there — 64 percent overall — but was still 82 percent effective at preventing severe disease. The FDA report also indicates that the vaccine protects against other variants from Britain and Brazil, too.

Advertisement

3. How Is It Different From the Moderna and Pfizer Vaccines?

The most basic difference is that the Johnson & Johnson vaccine is an adenovirus vector vaccine, while the Moderna and Pfizer vaccines are both mRNA vaccines. Messenger RNA vaccines use genetic instructions from the coronavirus to tell a person's cells to make the spike protein, but these don't use another virus as a vector. There are many practical differences, too.

Both of the mRNA-based vaccines require two shots. The Johnson & Johnson vaccine requires only a single dose. This is key when vaccines are in short supply.

The Johnson & Johnson vaccine can also be stored at much warmer temperatures than the mRNA vaccines. The mRNA vaccines must be shipped and stored at below-freezing or subzero temperatures and require a complicated cold chain to safely distribute them. The Johnson & Johnson vaccine can be stored for at least three months in a regular refrigerator, making it much easier to use and distribute.

As for efficacy, it is difficult to directly compare the Johnson & Johnson vaccine with the mRNA vaccines due to differences in how the clinical trials were designed. While the Moderna and Pfizer vaccines are reported to be approximately 95 percent effective at preventing illness from COVID-19, the trials were done over the summer and fall of 2020, before newer more contagious variants were circulating widely. The Moderna and Pfizer vaccines might not be as effective against the new variants, and Johnson & Johnson trials were completed more recently and take into account the vaccine's efficacy against these new variants.

covid vaccine site
Military personnel prepare for the opening of a mass COVID-19 vaccination site run by FEMA in the Queens borough of New York, on Feb. 24, 2021.
SETH WENIG/POOL/AFP via Getty Images

Advertisement

4. Should I Choose One Vaccine Over Another?

Although the overall efficacy of the Moderna and Pfizer vaccines is higher than the Johnson & Johnson vaccine, you should not wait until you have your choice of vaccine, which is likely a long way off anyway. The Johnson & Johnson vaccine is nearly as good as the mRNA-based vaccines at preventing serious disease, and that's what really matters.

The Johnson & Johnson vaccine and other viral-vector vaccines like the one from AstraZeneca are particularly important for the global vaccination effort. From a public health perspective, it's important to have multiple COVID-19 vaccines, and the Johnson & Johnson vaccine is a very welcome addition to the vaccine arsenal. It doesn't require a freezer, making it much easier to ship and store. It's a one-shot vaccine, making logistics much easier compared with organizing two doses per person.

As many people as possible need to be vaccinated as quickly as possible to limit the development of new coronavirus variants. Johnson & Johnson is expected to ship out nearly 4 million doses as soon as Monday, March 1. Having a third authorized vaccine in the U.S. will be a big step toward meeting vaccination demand and stopping this pandemic.

Maureen Ferran is an associate professor of biology at the Rochester Institute of Technology. Ferran does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

This article is republished from The Conversation under a Creative Commons license. You can find the original article here.

Advertisement

Originally Published: Feb 26, 2021

Games

Advertisement

Loading...